<DOC>
	<DOC>NCT00449813</DOC>
	<brief_summary>The aim of the study is to compare two different endpoint measures: heartburn as assessed by the physicians versus gastroesophageal reflux disease (GERD)-related symptoms as assessed by the patient using the ReQuestâ„¢ questionnaire. The assessment is made in GERD-patients treated with a daily dose of 40 mg oral pantoprazole over an 8-week period.</brief_summary>
	<brief_title>The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Written informed consent Outpatients of at least 18 years of age History of GERDrelated symptoms of at least 6 months prior to baseline visit Endoscopicallyconfirmed GERD or nonerosive GERD ZollingerEllison syndrome or other gastric hypersecretory condition Acute peptic ulcer and/or ulcer complications Pyloric stenosis Severe or unstable cardiovascular, pulmonary, and/or endocrine disease Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of reliable contraception in women of childbearing potential Intake of any medication for the purpose of eradication of Helicobacter pylori (H. pylori) within the last 28 days prior to study start Intake of systemic glucocorticoids or nonsteroidal antiinflammatory drugs including cyclooxygenase2 (COX2) inhibitors for more than 3 consecutive days within the last 28 days prior to study start; with the exception of acetylsalicylic acid not more than 150 mg per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Gastroesophageal reflux disease (GERD)</keyword>
	<keyword>Non erosive reflux disease (NERD)</keyword>
</DOC>